SCHEDULE: Vanguard Group Adjusts Protagonist Therapeutics Reporting

The Vanguard Group reports 0% beneficial ownership in Protagonist Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 5 to Schedule 13G regarding its holdings in Protagonist Therapeutics Inc. common stock.
• As of the event date March 13, 2026, The Vanguard Group reports 0% beneficial ownership of Protagonist Therapeutics Inc. common stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis).
• Consequently, The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities beneficially owned by these disaggregated entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral for Protagonist Therapeutics, as it primarily reflects an administrative change in The Vanguard Group's reporting structure rather than a fundamental shift in investment strategy.

Positives

• Clear disclosure of the internal realignment and its impact on beneficial ownership reporting, enhancing transparency regarding The Vanguard Group's compliance with SEC regulations.

Negatives

• The Vanguard Group, a significant institutional investor, no longer directly reports beneficial ownership of Protagonist Therapeutics Inc. common stock, which could be misinterpreted by some investors as a full divestment.

Risks

• Potential for misinterpretation by investors regarding The Vanguard Group's overall investment strategy or continued interest in Protagonist Therapeutics, given the 0% reported beneficial ownership by the parent entity.

Future Outlook

NA

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."
• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that such internal realignments by large asset managers like The Vanguard Group are primarily administrative and regulatory compliance matters. While they change the reporting entity, they do not necessarily indicate a change in the underlying investment thesis or total exposure of the broader Vanguard ecosystem to Protagonist Therapeutics. This is a common practice for large, diversified investment firms to streamline reporting and comply with specific SEC guidance.

Stakeholder Impact

• Shareholders of Protagonist Therapeutics: May initially perceive a major institutional investor has fully exited, potentially leading to negative sentiment, though the underlying holdings may still exist under different Vanguard entities.
• The Vanguard Group's Clients/Funds: The internal realignment aims to streamline reporting, which could improve transparency for clients regarding specific fund holdings.

Key Dates

Recommendation

The filing is an administrative update from The Vanguard Group regarding its beneficial ownership reporting due to an internal realignment. It does not provide new fundamental information about Protagonist Therapeutics' operations, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should understand this is a procedural change, not necessarily a full divestment by all Vanguard-managed funds.

Keywords

Protagonist Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, SEC filing, common stock, investment realignment